Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Appoints Chris Tovey as chief executive officer from September 1, taking over from Interim CEO Debra Barker who will return to position of non-executive director. The company announces departure of Chair Nick Rodgers, expects to announce new outside chair shortly.
Incoming Chief Executive Officer Chris Tovey said: "I am delighted to be joining Destiny, where there is an incredibly exciting opportunity to progress a highly innovative product pipeline, targeting prevention of infections and representing powerful new offerings to the healthcare community that is seeking new approaches to treat and prevent infectious diseases."
Current stock price: 29.00 pence, up 7.8% on Wednesday in London
12-month change: down 24%
By Will Neill, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved
Destiny Pharma. (DEST)